Duration of Pertussis Immunity After DTaP Immunization: A Meta-analysis

  title={Duration of Pertussis Immunity After DTaP Immunization: A Meta-analysis},
  author={Ashleigh McGirr and David N. Fisman},
  pages={331 - 343}
BACKGROUND AND OBJECTIVES Pertussis incidence is increasing, possibly due to the introduction of acellular vaccines, which may have decreased the durability of immune response. [] Key MethodWe searched Medline and Embase for articles published before October 10, 2013. Included studies contained a measure of long-term immunity to pertussis after 3 or 5 doses of DTaP. Twelve articles were eligible for inclusion; 11 of these were included in the meta-analysis.

Figures and Tables from this paper

Duration of Immunity and Effectiveness of Diphtheria-Tetanus-Acellular Pertussis Vaccines in Children.

The results of this study suggest that temporal trends in the odds of acquiring pertussis are an unreliable measure of the durability of vaccine-induced protection and that control strategies should be based on the best available estimates of vaccine properties and the age structure of the transmission network.

Effectiveness of pertussis vaccination and duration of immunity

High early effectiveness of the pertussis vaccine that rapidly declined as time since last vaccination surpassed 4 years, particularly with acellular vaccine priming.

Rethinking the efficacy of acellular pertussis vaccines for primary immunization

The results show that temporal trends in the odds of acquiring pertussis are a seriously flawed measure of the durability of vaccine-induced protection and argue that control strategies should be based upon the best available estimates of vaccine properties and the age-structure of the transmission network.

Protective Effect of Contemporary Pertussis Vaccines: A Systematic Review and Meta-analysis.

Although all contemporary aP and wP formulations protect against pertussis disease, in this meta-analysis the point estimate for short-term protective effect against WHO-defined pertussi in young children was lower for currently available aP vaccines than wP vaccines.

Acellular Pertussis Vaccine Effectiveness Over Time

Compared with children fully DTaP vaccinated, unvaccinated and undervaccinated children were at a greater risk of pertussis, suggesting that suboptimal vaccine effectiveness played a major role in recent pertussedis epidemics.

Pertussis Prevention: Reasons for Resurgence, and Differences in the Current Acellular Pertussis Vaccines

The results of a Consensus Conference organized by the World Association for Infectious Disease and Immunological Disorders on June 22, 2018, in Perugia, Italy, are reported, with the goal of evaluating the most important reasons for the pertussis resurgence and the role of different aPVs in this resurgence.



Waning protection after fifth dose of acellular pertussis vaccine in children.

Pertussis waned during the 5 years after the fifth dose of DTaP, and the odds of acquiring pertussis increased by an average of 42% per year after 2006 to 2011.

Immunity to pertussis 5 years after booster immunization during adolescence.

  • K. EdelmanQiushui He J. Mertsola
  • Medicine, Biology
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2007
The results of the present study of adolescents indicate that the interval between acellular pertussis booster immunizations might be extended beyond 5 years.

Waning Immunity to Pertussis Following 5 Doses of DTaP

Continuing to monitor disease burden and vaccine effectiveness in fully vaccinated children in coming years will be important to assess ongoing risk as additional cohorts vaccinated solely with acellular pertussis vaccines are introduced.

Association of childhood pertussis with receipt of 5 doses of pertussis vaccine by time since last vaccine dose, California, 2010.

Among children in 15 California counties, children with pertussis, compared with controls, had lower odds of having received the 5-dose DTaP series; as time since lastDTaP dose increased, the odds increased, which is consistent with a progressive decrease in estimated vaccine effectiveness each year after the final dose of pertussi vaccine.

A ten year follow-up after immunization with a two component acellular pertussis vaccine.

The study showed that antitoxin concentrations are maintained in a situation of endemic pertussis and indicated that the long term protection after an acellular booster was good, irrespective of type of vaccine or the number of doses of a cellular vaccine given for priming.

Pertussis Vaccine Effectiveness Among Children 6 to 59 Months of Age in the United States, 1998–2001

The effectiveness of the pertussis vaccine effectiveness (VE) among US children 6 to 59 months of age was measured to measure the availability of 3 DTaP and 2 DTP vaccines and the likelihood of the vaccines being used interchangeably to vaccinate children with the recommended 5-dose schedule.

Pertussis Resurgence: Diagnosis, Treatment, Prevention, and Beyond

A MEDLINE search of literature from 1966–2006 was performed to evaluate and review the existing data on immunity to and prevention or treatment of B. pertussis infections and new recommendations by the Advisory Committee on Immunization Practices to assist in preventing outbreaks of this infectious disease.

Long-Term Pertussis-Specific Immunity after Primary Vaccination with a Combined Diphtheria, Tetanus, Tricomponent Acellular Pertussis, and Hepatitis B Vaccine in Comparison with That after Natural Infection

The results show that the immune responses induced by primary pertussis vaccination are qualitatively and quantitatively similar to those seen in children who recovered from natural infection and highlight the need for booster immunization with pertussi vaccines in order to maintain adequate levels of a specific immune response to B. pertussedis.

The present and future control of pertussis.

  • J. Cherry
  • Medicine
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2010
The data support the need for a decennial booster dose of diphtheria toxoid, whereas some might interpret their teta- data as suggesting a lack of reactogenicity in Tdap after a second decennial dose in young adults.